GI CANCERS

In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.

The FDA has accepted the biologics license application of tislelizumab in combination with chemotherapy for the treatment of locally advanced or metastatic gastric or gastroesophageal cancers.

The FDA has granted an investigational new drug application to the investigational chimeric antigen receptor T-cell therapy IMC001 for the treatment of EpCAM-positive advanced gastrointestinal tumors.

IMM-1-104 has gained a fast track designation from the FDA for the treatment of patients with pancreatic ductal adenocarcinoma who have progressed after 1 line of treatment.

A phase 2 trial for the treatment of gastric, esophageal, and gastroesophageal junction cancer is evaluating agenT-797 with botensilimab, balstilimab, ramucirumab, and paclitaxel.

Liposomal irinotecan with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX) is now an FDA-approved treatment option for patients with metastatic pancreatic ductal adenocarcinoma.

212PB-DOTAMTATE is the first targeted alpha therapy to receive a breakthrough therapy designation in this intent-to-treat population.

In separate virtual live events, R. Kate Kelley, MD, with Daneng Li, MD, and Chih-Yi (Andy) Liao, MD, with Anjana Pillai, MD, discussed imaging and treatment for a patient with biliary tract cancer with event participants.

For Gallbladder Cancer Awareness Month, Horacio J. Asbun, MD, and Domenech Asbun, MD, shared their thoughts and strategies for treating patients with this disease from the surgical and clinical sides.

Fruquintinib combined with paclitaxel significantly improved progression-free survival in patients with advanced gastric/GEJ cancer compared with paclitaxel alone.

In an interview with Targeted Oncology, Sanjay Goel, MD, MS, discussed the mystery of cachexia in pancreatic cancer and why it remains a challenging symptom to target.

Following ASCO GI 2024, Pamela L. Kunz, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the CheckMate 8HW study investigating nivolumab plus ipilimumab in MSI-high/mismatch repair deficient metastatic colorectal cancer.

During a live event on Twitter/X, Pashtoon Kasi, MD, MS, discussed the potential of ctDNA and other advancements that have the potential to improve the lives of patients with GI cancers.

Oncologists at Allegheny Health Network share updates on their latest approaches for optimizing surgical and systemic treatment in patients with pancreatic cancer.

In an interview with Targeted Oncology, Randeep Sangha, MD, discussed the background of the phase 1 study and the rationale for studying zelenirstat for the treatment of solid tumors and hematologic malignancies.

Using ctDNA to detect minimal residual disease in patients with stage II/III colorectal cancer appeared to show strong prognosis of disease recurrence and benefit to adjuvant chemotherapy.

The neoadjuvant administration of botensilimab/balstilimab resulted in strong responses in individuals with both resectable mismatch repair–proficient and –deficient colorectal cancer.

In the DeFianCe trial, the combination of DKN-01 with bevacizumab and chemotherapy is being investigated to assess the potential clinical benefits for patients diagnosed with microsatellite stable colorectal adenocarcinoma.

Results from the phase 3 FRESCO-2 trial substantiate the potential of fruquintinib to offer enhanced survival benefits and improved quality of life for individuals with metastatic colorectal cancer who have undergone prior treatments.

Results from the phase 3 CheckMate-8HW trial support first-line treatment with nivolumab plus ipilimumab as a standard-of-care option for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

The updated data of larotrectinib as a treatment in TRK fusion GI cancers continued to demonstrate optimal responses, survival, and safety.

From 2013 to 2022, the use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer, with a trend in patients aged 50 years and younger.

Fostroxacitabine bralpamide combined with lenvatinib showed acceptable safety and tolerability, while inducing promising efficacy in patients with hepatocellular carcinoma.

Neoadjuvant camrelizumab in combination with nab-paclitaxel and cisplatin exhibited enhanced pathological complete response compared to solitary chemotherapy in individuals diagnosed with esophageal squamous cell carcinoma.

The combination of neoadjuvant FLOT with durvalumab demonstrated enhanced pathological complete response compared to sole chemotherapy in individuals with resectable gastric and GEJ cancers, regardless of geographical location.

An immunotherapy combination with chemotherapy significantly extended survival and delayed cancer progression in patients with esophageal squamous cell carcinoma compared with standard chemotherapy alone.

ASKB589 exhibited anti-tumor activity when used alongside capecitabine and oxaliplatin, along with sintilimab, for the treatment of gastric or gastroesophageal junction cancers.

In patients who were administered nivolumab in conjunction with chemotherapy, there were enhancements observed in both overall survival and progression-free survival compared to those who received chemotherapy alone.

Findings from an observational investigation revealed that the combination of nivolumab and chemotherapy contributed to improve survival in individuals diagnosed with advanced gastrointestinal cancers.